Evidence map›Paper›PMID 33329526›Full record

ArticleFrontiers in immunology2020

Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.

Xuan Zhou, Sanfang Tu, Chunsheng Wang, Rui Huang, Lan Deng, Chaoyang Song, Chunyan Yue, Yanjie He, Jilong Yang, Zhao Liang and 10 more

Open access · goldAbstract readClinical Trial, Phase IMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 10 pooled it
2.9field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 10 syntheses or guidelines pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 4 institutions in 1 country.

Xuan ZhouDepartment of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Sanfang TuDepartment of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Chunsheng WangDepartment of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Rui HuangDepartment of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Lan DengDepartment of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Chaoyang SongDepartment of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Chunyan YueDepartment of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Yanjie HeDepartment of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Jilong YangDepartment of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Zhao LiangDepartment of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Anqin WuDepartment of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Meifang LiDepartment of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Weijun ZhouDepartment of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Jingwen DuDepartment of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Zhenling GuoDepartment of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Yongqian LiDepartment of Hematology, Shantou Central Hospital, Shantou, China.
Cheng JiaoDepartment of Research and Development, Geno-Immue Medical Institute, Shenzhen, China.
Yuchen LiuDepartment of Research and Development, Geno-Immue Medical Institute, Shenzhen, China.
Lung-Ji ChangDepartment of Research and Development, Geno-Immue Medical Institute, Shenzhen, China.
Yuhua LiDepartment of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Zhujiang Hospital · CNGuangzhou Regenerative Medicine and Health Guangdong Laboratory · CNUniversity of Electronic Science and Technology of China · CNShenzhen Genoimmune Medical Institute · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The administration of second- or third-generation anti-CD19 chimeric antigen receptor (CAR) T cells has remarkably improved the survival of patients with relapsed or refractory B cell malignancies. However, there are limited clinical results from fourth-generation CAR-T cell therapy, and the factors affecting response rate and survival have not been fully determined. Methods: Lymphoma patients with progression or relapse after intensive treatments, including hematopoietic stem cell transplantation, and life expectancy >2 months were enrolled in the study. Peripheral lymphocytes were collected through apheresis, and magnetically selected T cells were lentivirally transduced with a 4th-generation CAR featuring an anti-CD19 CAR and the iCasp9 suicide switch (4SCAR19). The patients received 4SCAR19 T cell infusion after approximately seven days of expansion and a conditioning regimen comprising cyclophosphamide/fludarabine. The efficacy, safety, and risk factors were evaluated. Results: A total of 21 patients with relapsed/refractory B cell non-Hodgkin lymphoma were enrolled and received 4SCAR19 T cell infusions at a median dose of 8.9×10 Conclusions: In this study, patients with relapsed or refractory B cell non-Hodgkin's lymphoma who received 4SCAR19 T cell therapy had durable responses and few of adverse events. The IPI model is suitable for evaluating the prognosis of patients receiving CAR-T cell therapy. Trial registration: Chinese Clinical Trial Registry (http://www.chictr.org.cn): ChiCTR-OOC-16007779.

Indexed as

AdultAgedAntigens, CD19Cytokine Release SyndromeFemaleFollow-Up StudiesHumansImmunotherapy, AdoptiveLeukopeniaLymphoma, Large B-Cell, DiffuseMaleMiddle AgedNeoplasm Recurrence, LocalNeutropeniaPrognosisProgression-Free SurvivalAntigens, CD19CD19 molecule, humanReceptors, Chimeric AntigenB cell lymphomaCD19chimeric antigen receptor T cellscytokine release syndromenon-Hodgkin’s lymphomas

Identifiers

PMID33329526
PMCPMC7731732
OpenAlexW3108364201

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.